Companies / South Africa
Tiger Looks To Roll Out ARVs
November 2006 | Company Finance AlertSouth African consumer goods group Tiger Brands is aiming to have a full range of antiretroviral (ARV) drugs available on the market in H107, challenging the primacy of local rival Aspen Pharmacare. The company needs a portfolio of 19 drugs to be able to take part in government ARV tenders and has spent more than ZAR50mn (US$6.91mn) on R&D. South Africa has one of the highest HIV/AIDS burdens in the world, with more than 9mn cases. AIDS activists claim that approximately 500,000 remain in need of ARVs, who are not receiving
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
